Market Place
Sourcing Support
Alumis Reveals 2025 Financials And Recent Milestones
19 Mar 2026 //
GLOBENEWSWIRE
Alumis Reports Phase 3 ONWARD Data for Envudeucitinib in Plaque
05 Jan 2026 //
GLOBENEWSWIRE
Alumis Reports Q3 2025 Financial Results And Recent Advances
13 Nov 2025 //
GLOBENEWSWIRE
Alumis To Participate In Upcoming November Investor Conferences
04 Nov 2025 //
GLOBENEWSWIRE
Alumis to Participate in Upcoming September Investor Conferences
29 Aug 2025 //
GLOBENEWSWIRE
Alumis Promotes Sanam Pangali to Chief Legal Officer
14 Jul 2025 //
GLOBENEWSWIRE
Alumis to Present at Jefferies Healthcare Investor Conference
29 May 2025 //
GLOBENEWSWIRE
Alumis Completes Merger with Acelyrin
21 May 2025 //
GLOBENEWSWIRE
Activist investor fails to derail Alumis` Acelyrin merger
14 May 2025 //
FIERCE BIOTECH
Alumis Reports Q1 2025 Financial Results and Recent Achievements
14 May 2025 //
GLOBENEWSWIRE
Alumis Stockholders Approve Merger with Acelryin
13 May 2025 //
GLOBENEWSWIRE
Acelyrin, Alumis Merger Approved to Form Immune Disease Biotech
13 May 2025 //
GLOBENEWSWIRE
Acelyrin Reiterates Benefits of Value-Maximizing Combo with Alumis
01 May 2025 //
GLOBENEWSWIRE
Investor pressures Acelyrin to exit Alumis merger and liquidate
30 Apr 2025 //
FIERCE BIOTECH
Alumis & Acelyrin Announce Amended Merger Agreement
21 Apr 2025 //
GLOBENEWSWIRE
Alumis and Acelyrin File Proxy for Merger
04 Apr 2025 //
GLOBENEWSWIRE
Alumis Reports 2024 Financials, Highlights Recent Gains
19 Mar 2025 //
GLOBENEWSWIRE
Alumis to Present at Leerink`s 2025 Global Healthcare Conference
10 Mar 2025 //
GLOBENEWSWIRE
Acelyrin Rejects Concentra’s Buyout Offer of Alumis Merger
06 Mar 2025 //
GLOBENEWSWIRE
Alumis To Present ESK-001 Ph 2 & Ph 3 Data At AAD 2025
28 Feb 2025 //
GLOBENEWSWIRE
Alumis Presents Ph 1 Data On A-005 TYK2 Inhibitor At ACTRIMS 2025
27 Feb 2025 //
GLOBENEWSWIRE
Alumis to Present at Oppenheimer 35th Annual Healthcare Conference
10 Feb 2025 //
GLOBENEWSWIRE
Acelyrin to be absorbed into Alumis in all-stock merger
08 Feb 2025 //
FIERCEBIOTECH
Alumis Strengthens Leadership Team with Key Appointments
28 Jan 2025 //
GLOBENEWSWIRE
Alumis Announces Positive Phase 1 Data for TYK2 Inhibitor A-005
19 Dec 2024 //
GLOBENEWSWIRE
Alumis Reports Q3 2024 Results & Key Achievements
13 Nov 2024 //
GLOBENEWSWIRE
Alumis to Participate in Guggenheim Healthcare Innovation Conf
04 Nov 2024 //
GLOBENEWSWIRE
Late-Breaking Data Of ESK-001 For Psoriasis At EADV Demonstrate
27 Sep 2024 //
GLOBENEWSWIRE
Alumis to Participate in Upcoming September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Alumis Reports Q2 2024 Results And Recent Achievements
13 Aug 2024 //
GLOBENEWSWIRE
Alumis Initiates Phase 3 Trial Of ESK-001 In Plaque Psoriasis
29 Jul 2024 //
GLOBENEWSWIRE
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
29 Jun 2024 //
REUTERS
Therapy developer Alumis prices U.S. IPO at about $902M
28 Jun 2024 //
REUTERS
Alumis Announces Pricing of Initial Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Alumis Eyes IPO Over $300M To Fund TYK2 Pipeline
24 Jun 2024 //
FIERCE BIOTECH
Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials
10 Jun 2024 //
FIERCE BIOTECH
Alumis: First Patient Dosed In Phase 1 Trial Of TYK2 Inhibitor A-005
30 Apr 2024 //
GLOBENEWSWIRE
Alumis to Participate in the 2024 Leerink Partners Global Biopharma Conference
11 Mar 2024 //
GLOBENEWSWIRE
Alumis closes a $259M Series C to back its TYK2, flirts with talk about an IPO
06 Mar 2024 //
ENDPTS
Alumis Announces Upsized $259M Series C Financing
06 Mar 2024 //
GLOBENEWSWIRE
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
01 Mar 2024 //
GLOBENEWSWIRE
Alumis Announces Initiation of Patient Dosing in Phase 2 Trial of ESK-001
28 Sep 2022 //
BUSINESSWIRE
Alumis Appoints Jörn Drappa as CMO and Roman G. Rubio as Senior Vice President
08 Sep 2022 //
BUSINESSWIRE
Alumis Expands Industry-Leading Leadership Team; Appoints General Counsel & CFO
06 Apr 2022 //
BUSINESSWIRE
Former Principia CEO Tapped to Lead Esker Therapeutics
24 Sep 2021 //
BIOSPACE
MyoKardia`s clinical ops lead jumps ship to Esker
20 Aug 2021 //
FIERCEBIOTECH
Esker Therapeutics Appoints Jeff Douglas as VP of Clinical Operations
19 Aug 2021 //
BUSINESSWIRE
Esker Therapeutics Appoints New Team Members and Board Director
21 Jul 2021 //
BUSINESSWIRE
Esker Therapeutics launches with $70M for autoimmune diseases
06 May 2021 //
FIERCEBIOTECH
Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases
05 May 2021 //
BUSINESSWIRE
